Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing
- PMID: 10710308
- DOI: 10.1126/science.287.5459.1816
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing
Abstract
Neisseria meningitidis is a major cause of bacterial septicemia and meningitis. Sequence variation of surface-exposed proteins and cross-reactivity of the serogroup B capsular polysaccharide with human tissues have hampered efforts to develop a successful vaccine. To overcome these obstacles, the entire genome sequence of a virulent serogroup B strain (MC58) was used to identify vaccine candidates. A total of 350 candidate antigens were expressed in Escherichia coli, purified, and used to immunize mice. The sera allowed the identification of proteins that are surface exposed, that are conserved in sequence across a range of strains, and that induce a bactericidal antibody response, a property known to correlate with vaccine efficacy in humans.
Comment on
-
Microbiology. A furtive pathogen revealed.Science. 2000 Mar 10;287(5459):1767-8. doi: 10.1126/science.287.5459.1767. Science. 2000. PMID: 10755929 No abstract available.
Similar articles
-
Complete genome sequence of Neisseria meningitidis serogroup B strain MC58.Science. 2000 Mar 10;287(5459):1809-15. doi: 10.1126/science.287.5459.1809. Science. 2000. PMID: 10710307
-
Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.Infect Immun. 2001 Jun;69(6):3762-71. doi: 10.1128/IAI.69.6.3762-3771.2001. Infect Immun. 2001. PMID: 11349041 Free PMC article.
-
Immune response to native NadA from Neisseria meningitidis and its expression in clinical isolates in Brazil.J Med Microbiol. 2003 Feb;52(Pt 2):121-125. doi: 10.1099/jmm.0.05017-0. J Med Microbiol. 2003. PMID: 12543917
-
The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.Contrib Microbiol Immunol. 1989;10:151-65. Contrib Microbiol Immunol. 1989. PMID: 2479499 Review. No abstract available.
-
Meningococcal vaccines.Expert Rev Vaccines. 2002 Jun;1(1):75-84. doi: 10.1586/14760584.1.1.75. Expert Rev Vaccines. 2002. PMID: 12908514 Review.
Cited by
-
Meningococcal outer membrane protein NhhA triggers apoptosis in macrophages.PLoS One. 2012;7(1):e29586. doi: 10.1371/journal.pone.0029586. Epub 2012 Jan 4. PLoS One. 2012. PMID: 22238624 Free PMC article.
-
Bacterial extracellular vesicle applications in cancer immunotherapy.Bioact Mater. 2022 Oct 31;22:551-566. doi: 10.1016/j.bioactmat.2022.10.024. eCollection 2023 Apr. Bioact Mater. 2022. PMID: 36382022 Free PMC article.
-
Prospects for subunit vaccines: Technology advances resulting in efficacious antigens requires matching advances in early clinical trial investment.Hum Vaccin Immunother. 2016 Dec;12(12):3103-3106. doi: 10.1080/21645515.2016.1216287. Epub 2016 Aug 5. Hum Vaccin Immunother. 2016. PMID: 27494532 Free PMC article.
-
Virulence determinants involved in differential host niche adaptation of Neisseria meningitidis and Neisseria gonorrhoeae.Med Microbiol Immunol. 2010 Aug;199(3):185-96. doi: 10.1007/s00430-010-0150-5. Epub 2010 Apr 9. Med Microbiol Immunol. 2010. PMID: 20379743 Review.
-
Pooled protein immunization for identification of cell surface antigens in Streptococcus sanguinis.PLoS One. 2010 Jul 26;5(7):e11666. doi: 10.1371/journal.pone.0011666. PLoS One. 2010. PMID: 20668678 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
